Esterase inhibitors as ester-containing drug stabilizers and their hydrolytic products: Potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 26, Issue 11, 2012, Pages 1291-1304

  Zheng, Naiyu ^a   Fung, Eliza N ^a   Buzescu, Adela ^a   Arnold, Mark E ^a   Zeng, Jianing ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; CHROMATOGRAPHIC ANALYSIS; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; ENZYMES; FLUORINE COMPOUNDS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

BIOANALYSIS; DIISOPROPYLFLUOROPHOSPHATE; HYDROLYTIC PRODUCT; LC-MS-MS; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; MATRICES EFFECT; PARAOXON; PHENYLMETHYLSULFONYL FLUORIDE; POST-COLUMN; SELECTED REACTION MONITORING;

ESTERS;

EID: 84860692467     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6230     Document Type: Article

References (34)

1. B. L. Ackermann, M. J. Berna, A. T. Murphy,. Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. Curr. Topics Med. Chem. 2002, 2, 53.
2. Y. Hsieh,. HPLC-MS/MS in drug metabolism and pharmacokinetic screening. Expert Opin. Drug Metab. Toxicol. 2008, 4, 93.
3. F. Saint-Marcoux, F. L. Sauvage, P. Marquet,. Current role of LC-MS in therapeutic drug monitoring. Anal. Bioanal. Chem. 2007, 388, 1327.
4. M. Ewles, L. Goodwin,. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 2011, 3, 1379.
5. H. Li, R. Ortiz, L. Tran, M. Hall, C. Spahr, K. Walker, J. Laudemann, S. Miller, H. Salimi-Moosavi, J. W. Lee,. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem. 2012, 84, 1267.
6. M. Jemal, Y. Q. Xia,. LC-MS Development strategies for quantitative bioanalysis. Curr. Drug Metab. 2006, 7, 491.
7. R. N. Xu, L. Fan, M. J. Rieser, T. A. El-Shourbagy,. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J. Pharm. Biomed. Anal. 2007, 44, 342.
8. N. Weng, T. D. J. Halls,. Systematic troubleshooting for LC/MS/MS. Part 1: Sample preparation and chromatography. BioPharm. 2001, 14, 28.
9. N. Weng, T. D. J. Halls,. Systematic troubleshooting for LC/MS/MS. Part 2: Large-scale LC/MS/MS and automation. BioPharm. 2002, 15, 22.
10. R. Bakhtiar, T. K. Majumdar,. Tracking problems and possible solutions in the quantitative determination of small molecule drugs and metabolites in biological fluids using liquid chromatography-mass spectrometry. J. Pharmacol. Toxicol. Methods 2007, 55, 262.
11. M. Jemal, Z. Ouyang, Y. Q. Xia,. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr. 2010, 24, 2.
12. J. Chen, Y. Hsieh,. Stabilizing drug molecules in biological samples. Ther. Drug Monit. 2005, 27, 617.
13. J. Chen, G. Wang, J. M. Brisson, Y. Hsieh,. Methodologies for stabilization of pharmaceuticals in biological samples. Am. Lab. 2005, 37, 12.
14. D. Dell,. Labile metabolites. Chromatographia 2004, 59, S139.
15. C. T. Viswanathan, S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, R. Weiner,. Workshop/Conference Report-Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. AAPS J. 2007, 9, E30.
16. C. Briscoe, D. S. Hage,. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis. 2009, 1, 205.
17. D. E. Mulvana,. Critical topics in ensuring data quality in bioanalytical LC-MS method development. Bioanalysis 2010, 2, 1051.
18. W. Li, J. Zhang, F. L. Tse,. Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr. 2011, 25, 258.
19. T. Satoh, P. Taylor, W. F. Bosron, S. P. Sanghani, M. Hosokawa, B. N. La Du,. Current progress on esterases: from molecular structure to function. Drug Metab. Dispos. 2002, 30, 488.
20. M. Koika, J. Höchel, H. Gieschen, H. H. Borchert,. Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. J. Pharm. Biomed. Anal. 2010, 51, 664.
21. Y. Yoshigae, T. Imai, M. Taketani, M. Otagiri,. Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma. Chirality 1999, 11, 10.
22. S. Kudo, K. Umehara, M. Hosokawa, G. Miyamoto, K. Chiba, T. Satoh,. Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation. J. Pharmacol. Exp. Ther. 2000, 294, 80.
23. S. Takai, A. Matsuda, Y. Usami, T. Adachi, T. Sugiyama, Y. Katagiri, M. Tatematsu, K. Hirano,. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol. Pharm. Bull. 1997, 20, 869.
24. J. Zhang, M. W. Fariss,. Thenoyltrifluoroacetone, a potent inhibitor of carboxylesterase activity. Biochem. Pharmacol. 2002, 63, 751.
25. S. Yamaori, N. Fujiyama, M. Kushihara, T. Funahashi, T. Kimura, I. Yamamoto, T. Sone, M. Isobe, T. Ohshima, K. Matsumura, M. Oda, K. Watanabe,. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab. Pharmacokinet. 2006, 21, 147.
26. B. Li, M. Sedlacek, I. Manoharan, R. Boopathy, E. G. Duysen, P. Masson, O. Lockridge,. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70, 1673.
27. M. N. Samtani, M. Schwab, P. W. Nathanielsz, W. J. Jusko,. Stabilization and HPLC analysis of betamethasone sodium phosphate in plasma. J. Pharm. Sci. 2004, 93, 726.
28. M. Shipkova, V. M. Armstrong, M. Oellerich, E. Wieland,. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 2003, 25, 1.
29. S. Takahashi, M. Katoh, T. Saitoh, M. Nakajima, T. Yokoi,. Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. J. Pharm. Sci. 2008, 97, 5434.
30. J. Zeng, D. Onthank, P. Crane, S. Unger, N. Zheng, S. Pasas-Farmer, M. Arnold,. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry-evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852, 77.
31. E. Chambers, D.M. Wagrowski-Diehl, Z. Lu, J. R. Mazzeo,. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852, 22.
32. R. Bonfiglio, R. C. King, T. V. Olah, K. Merkle,. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13, 1175.
33. R. King, R. Bonfiglio, C. Fernandez-Metzler, C. Miller-Stein, T. Olah,. Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. Mass Spectrom. 2000, 11, 942.
34. W. Shou, N. Weng,. Post-column infusion study of the 'dosing vehicle effect' in the liquid chromatography/tandem mass spectrometric analysis of discovery pharmacokinetic samples. Rapid Commun. Mass Spectrom. 2003, 17, 589.